key: cord-0894574-cccmnctx
authors: Campos-Ferreira, D.; Visani, V.; Córdula, C; Nascimento, G.A.; Montenegro, L.M.L.; Schindler, H.C.; Cavalcanti, I.M.F.
title: COVID-19 challenges: from SARS-CoV-2 infection to effective point-of-care diagnosis by electrochemical biosensing platforms
date: 2021-09-09
journal: Biochem Eng J
DOI: 10.1016/j.bej.2021.108200
sha: 5b9d423960b90f85b45f206af46e2c02908d802d
doc_id: 894574
cord_uid: cccmnctx

In January 2020, the World Health Organization (WHO) identified a new zoonotic virus, SARS-CoV-2, responsible for causing the COVID-19 (coronavirus disease 2019). Since then, there has been a collaborative trend between the scientific community and industry. Multidisciplinary research networks try to understand the whole SARS-CoV-2 pathophysiology and its relationship with the different grades of severity presented by COVID-19. The scientific community has gathered all the data in the quickly developed vaccines that offer a protective effect for all variants of the virus and promote new diagnostic alternatives able to have a high standard of efficiency, added to shorter response analysis time and portability. The industry enters in the context of accelerating the path taken by science until obtaining the final product. In this review, we show the principal diagnostic methods developed during the COVID-19 pandemic. However, when we observe the diagnostic tools section of an efficient infection outbreak containment report and the features required for such tools, we could observe a highlight of electrochemical biosensing platforms. Such devices present a high standard of analytical performance, are low-cost tools, easy to handle and interpret, and can be used in the most remote and low-resource regions. Therefore, probably, they are the ideal point-of-care diagnostic tools for pandemic scenarios.

Since January 2020, the world has faced an infectious disease outbreak caused by a new zoonotic virus, SARS-CoV-2, responsible for the new coronavirus disease .

Research has shown that emerging and re-emergence contagious diseases with pandemic potential have occurred regularly throughout human history ( Fig.1 ) since the Neolithic Era [1] [2] [3] [4] . A new infectious disease is often associated with the evolution of pathogens over time (genetic plasticity: mutation, re-assortment, and recombination) [5] . However, there are other conditions involved in the epidemic outbreaks [6] , such as environmental (climate changes), ecological (deforestation), social (political and economic), and cultural factors (religion and eating habits) [7, 8] .

Around 75% of epidemic diseases have a zoonotic origin (pathogens jump from a vertebrate animal to a human). Transmission can occur by direct contact with the animal, vectors (e.g., fleas, ticks, and mosquitoes), or indirect contact, such as food and water contamination [9] . Among the pathogens that managed to cross the species barrier (animal-human), about 44% have RNA viral origin [10] . Classic examples include H1N1, Hedra virus, Nipah virus, and human coronavirus (HCoV).

Although the response to epidemic outbreaks (restricted region) and natural

In December 2019, many patients were diagnosed with unexplainable pneumonia. All patients, initially, were epidemiologically associated with the Huanan market from Wuhan province, China. WHO was alerted for the possibility of an unknown viral outbreak. In January 2020, these cases of pneumonia and a new HCoV type were associated [40] .

The phylogenetic analysis showed that this new HCoV presented more than 95% homology with bat coronavirus and more than 80% similarity with SARS-CoV [41] .

Given this homology, the new HCoV was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV), causing COVID-19 [40] .

On August 20, 2021 (July 19, 2021) , the USA presents the most confirmed cases (33, 723, 155) , followed by India (31, 144, 229) and Brazil (19, 342, 448) . The countries most affected in the first quarter of the pandemic, China and Italy, apparently managed to contain the outbreak and reduce the virus spread, currently presenting 119,698 and 4,287,458 of the confirmed cases (cumulative total), respectively. About the death numbers (cumulative total) caused by COVID-19, the country that is currently in the first position is the USA (603,790), followed by Brazil (541,266) and India (414, 108) . Italy is in eleventh (127, 867) and China is in ninety-eighth position (5.616) [42] .

The viral infection starts with the entrance of the virus into host cells. In the case of HCoVs, the RBD domain present in the S1 subunit of S protein recognizes the receptor located on the host's cell surface, initiating virus entrance into the cytosol. In both SARS-CoVs, the RBD domain specifically recognizes angiotensin-converting enzyme-2 (ACE2) receptor in host surface cell, whereas in the MERS-CoV, the RBD domain specifically recognizes dipeptidyl-peptidase-4 (DPP4) receptor, also called CD26 [43] .

Although the entry of the SARS-CoV-2 into the host's cell occurs through the attachment between ACE2 receptor and S protein, new researches have shown that S J o u r n a l P r e -p r o o f protein can also bind to other receptors, such as NRP1 (neuropilin-1) receptor [44] ; however its mechanism is not yet fully understood. Native S protein is present on the viral envelope surface in its closed form (inactive S protein), in which RBDs domains are inaccessible to the cell receptor. After protein cleavage, the S1 subunit opens (active S protein), exposing the RBD domain [45] . Depending on the type of protease present in the host's tissue, SARS-CoV-2 can enter cells by two distinct pathways, the early (non-endocytic) and the late (endocytic) pathways. Proteases expressed in the cellular membrane, such as trypsin, furin, and TMPRSS2, lead SARS-CoV-2 to the non-endocytic pathway. These host's enzymes cleave the S protein, causing conformational changes that expose the S2 subunit and, consequently, virus fusion immediately with the host's plasma membrane [43] . In the absence of those enzymes, the virus enters by the late pathway, within vesicles (endosomes) after S protein cleavage by endosomal proteases (clathrin and non-clathrin types) [44] . The non-endocytic pathway shows to be much more efficient, reaching an infection rate of 100 to 1,000 times higher [46] . ACE2 and NRP1 receptors are expressed in multiple tissues from the human body, as oral mucosa, lungs, kidneys, liver, heart, intestines, brain, blood vessels, and others [47] . That is why SARS-CoV-2 also can invade these tissues and induce systemic inflammation, leading to multiple organ dysfunction syndromes [48] . Much research has shown that SARS-CoV and SARS-CoV-2 recognize the same host-receptor.

However, SARS-CoV-2 presents greater pathogenicity and is more virulent than SARS-CoV. These features are due to some alterations found in the SARS-CoV-2 ( Fig.2) .

Such as (i) attachment to more than one receptor (ACE2 and NRP1) [44] ; (ii) entrance by two different pathways [46] ; (iii) cleavage site for furin protease in the S protein [49] ; and structural differences in RBD domain that provides more binding motif to ACE2 receptor, favoring more vital interaction [50] .

According to CDC [51] , the primary SARS-CoV-2 infection route exposes to respiratory droplets carrying the infectious virus. Virus-containing respiratory droplets can spread when an infected person (symptomatic or asymptomatic) exhales droplets (breathing, speaking, singing, coughing, sneezing) close to another person. However, J o u r n a l P r e -p r o o f less common but possible is the transmission by contact with a surface that has been contaminated [51] .

WHO and CDC suggest that the SARS-CoV-2 RNA shedding period (time between exposure to the pathogen and first symptoms appearance) varies from 2 to 14 days with an average of approximately five days, similar to SARS-CoV [52] . However, SARS-CoV-2 duration in the human body is not yet fully understood since it can vary from person to person. Some studies have reported that time may be more prolonged.

Zhou et al. [53] did a retrospective study with 191 patients from Wuhan hospitals (China) and observed that SARS-CoV-2 RNA could be detectable for an average period of 20 days, with the shortest time eight days and the longest, 37 days (more than one month). Similar results were observed for Mancuso et al. [54] [55] . Other researchers also analyzed samples from Wuhan hospital, but these studies took samples from infected patients at different periods. They reported that the average of the RNA shedding was 92 days, and the longest was 118 days (approximately four months) [56] . Thus, the presence of SARS-CoV-2 RNA in the human body can be longer than initially suspected. However, there is still insufficient data to affirm whether this prolonged time of the virus in the body may be related to a more extended transmission period [57] .

SARS-CoV-2 infection induces the production of three antibodies (IgA, IgM, and IgG). The seroconversion process can begin simultaneously or sequentially from the 7º to 14º day (on average 5º days) after the appearance of the first symptoms [58] .

IgA and IgM antibodies provide early defense, while IgG is responsible for long-term immunity and immunological memory. SARS-CoV-2 IgM e IgG can be detectable from 4º and 7º day of the initial symptoms, respectively [59] , unlike SARS-CoV-2 IgA, which can be detectable from 2º day [60] . Studies show that the IgA levels were significantly higher than those of IgM in both severe and non-severe patients, making it a pivotal biomarker to COVID-19 pathogenesis [60, 61] It is not yet clear how long the organism can provide enough IgG titers to keep immunization. Research shows that antibody titers decrease 2 to 6 months after acute J o u r n a l P r e -p r o o f infection, indicating that reinfection may occur [62] . Reinfection is occurring in diverse countries. However, there is not yet a consensus about this process, since it may be associated with: (i) non-durable protective immunity [58] ; (ii) different strains of the same virus [63] or; (iii) both [62] .

Older age, pre-existing comorbidities (chronic hypertension, diabetes, obesity, chronic lung disease, cardiovascular disease), and pregnancy are considered risk factors for developing severe COVID-19 [64] . So far, little information about vertical transmission is available, but there are some report-cases about the SARS-CoV-2 RNA presence in the fetal side of the placenta. Most children do not present symptoms, but they are considered one of the main COVID-19 transmitting agents for close family members [65] .

Infection and death rates have been distinctive both within the same country and among countries [66, 67] . Moreover, it is essential to highlight that the behavior of COVID-19 in different continents is unclear [40] . That reinforces how much we have yet to learn about COVID-19. Aspects of SARS-CoV-2 infection lika pathogenicity, host's immune response, ethnicity, viral mutation rate, rapid variant appearance and vaccine efficiency are not fully understood, motivating even more scientific community to elucidating all questions involved in SARS-CoV-2 infection.

Studies carried out by WHO and CDC reported the presence of multiple SARS-CoV-2 variants circulating the world. Analysis of 10,022 SARS-CoV-2 genomes revealed more than 67,700 variants [68] . The term "variant" or "strain" designates the viral particle with one or more mutations, leading to changes in some phenotypic features, antigenicity, transmission, or virulence [69] . One of the most worrying mutations in the SARS-CoV-2 was point mutation in the S gene (from ASP614 to GLY614), giving rise to a new strain called D614G. This amino acid change allowed the virus to increase its transduction and infection capacity up to 8X [70] .

According to CDC, the D614G strain has caused great concern, since from this [71] . However, the variant status might escalate or deescalate based on emerging scientific evidence; therefore, CDC constantly updates the ranking of each variant [72] .

WHO classifies variants according to CDC; however, it differs from the United States classification. Due to these differences, WHO proposed using Greek letters (label), such as Alpha, Beta, Gamma, as a practical way of discussing variants by nonscientific audiences. The variants and their classifications are described in table 1 [72] .

VOIs present genetic modifications that change to receptor binding and decrease antibodies functions, reducing the efficacy of the diagnostic, therapy, and vaccination and increasing the transmissibility and disease severity. VOCs present an improvement of the attributes found in VOIs. Such variants reduce diagnostic capability; they also increase the virus's resistance to one or more classes of therapies, and significantly decrease the host immune function and the protective effect of the vaccines, raising the transmissibility and disease severity (e.g., increased hospitalizations or deaths). These variant types might require one or more appropriate public health actions, such as notification to WHO; efforts to spread control (testing and quarantine implementation); research to determine mutation rate and update in the diagnostics, treatments, and vaccines; and closely monitoring by federal agencies. VOHC has all attributes found in the VOCs; furthermore several attributes increase the concern level by health agencies.

Fortunately, to date, no variant has been found to belong to this classification. Variants of this classification would have high impacts on medical countermeasures, such as a high increase in the diagnosis failure; significant reduction in vaccine effectiveness; reduced susceptibility to the various approved therapies; increased hospitalizations, and high severe clinical disease, with increased mortality [72] .

As an RNA virus, SARS-CoV-2 presents a propensity for rapid evolution, which results in a great diversity of variants with different characteristics from their prior strain. The first dominant variant identified was D614G, and since then, scientists have described several others, some of which are considered VOCS.

One of the main concerns among SARS-CoV-2 variants is the B. [75] . The L452R mutation is more transmissible and has greater efficiency for immune evasion in vaccine sera; P681R increases transmission, and T478K generates greater infectivity [76] .

Reseachs shows that the B. Delta plus variant has the addition of a point mutation, K417N, that is associated with immune escape, although its impact on transmissibility remains unclear [80] . In the original strain, RBD K417 residue is linked to ACE2 D30 residue by a salt bridge, considered one of the strongest non-covalent bonds. Thus, these residues contribute to the high binding affinity of SARS-CoV-2 to the ACE2 receptor [81] . Although K417N mutation loses three atomic contacts, reducing the contact of this residue to D30 of ACE2 and destabilizing the salt bridge, it increases by six atomic contacts the binding of the neighboring L455 to D30 of ACE2. Thus, K417N mutation slightly increases the binding affinity of S protein to ACE2 [82, 83] .

Many aspects of the Delta plus variant still need to be better studied. It remains unclear whether this additional mutation will make the Delta plus variant more transmissible, infectious, or resistant to antibodies than the original Delta variant.

Another point to be clarified is how effective the current vaccines will be against this new variant.

J o u r n a l P r e -p r o o f Rapid diagnostic, social isolation and masks are critical for control outbreaks and prevent viral spread. COVID-19 has non-specific manifestations, which can range from no symptoms to severe symptoms and death. Such a non-specificity aspect can be a problem for the health system because it can hamper correct diagnosis and epidemiological mapping (Fig.3A) .

Health organizations recommend reverse transcription-polymerase chain reaction (RT-PCR) as the "gold standard" for the SARS-CoV-2 RNA detection [84] and serologic assay to identified SARS-CoV-2 antibodies from clinical specimens [85] [86] [87] .

Nucleic acid assay identifies viral gene presence, measures active infection and guides public authority to contain the viral spread. Antibodies detection tests identify previous infections, helping to understand the behavior and progression of the disease, contributing to epidemiological data survey.

On June 11, 2020, WHO added the chest-image tools to the test list for COVID-19 diagnostic workup [88] . Among various imaging tools, the chest computed tomographic (CCT) showed greater sensitivity [89] . CCT is a routine technique for lung lesions evaluation in patients with some pulmonary dysfunction. Consequently, CCT can help in COVID-19 diagnostic and progression (from symptom presentation to home discharge). However, CCT is an option cases like RT-PCR unavailable; RT-PCR result delayed; symptomatic patient with negative RT-PCR; patients with moderate to severe symptoms, which present some risk-factor; and patients with worsening of the respiratory condition [88, 90] . In this way, CCT can be an integrated part of the medical screening system, particularly for patients who need emergency care.

The start point for COVID-19 diagnostic is SARS-CoV-2 RNA detection by nucleic acid amplification tests (NAATs). NAATs assays can amplify low numbers of DNA copies in millions of orders of magnitude with high sensitivity and specificity, J o u r n a l P r e -p r o o f being excellent tools for the early diagnosis of infectious diseases. WHO recommends using RT-PCR, a reverse transcription reaction followed by PCR, for SARS-CoV-2 RNA detection utilizing samples collected from the upper respiratory tract for spontaneously breathing patients (oropharynx and nasopharynx regions) and lower respiratory tract for mechanically ventilated patients [91] .

The targets for SARS-CoV-2 RNA detections, approved by CDC and WHO, have some distinctions. N1 and N2 genes are recommended by CDC [92] , while RdRp, E, and N genes are recommended by WHO [91] . E gene is the first line-screening assay, and RdRp and N genes are used for confirmatory tests. The gene human-RNase P (RP)

is a positive control [93] .

Although the RT-PCR technique is well known as an accurate method for detecting viral genetic material, many studies show that this technique can present falsenegative results for SARS-CoV-2 RNA [94] [95] [96] . Many factors may generate falsenegative results. Two critical points are sample quality (stage of the disease, viral load, virus replication, RNA extraction, location, and collection way) and the PCR assay (reagents, melting temperature, primers, and probes sets) [91, 97] .

Additional limiting factors for extensive usage of NAATs for infection disease diagnosis are infrastructure, high-cost reagents and equipment, refrigeration for reagents and samples, and trained professionals. Due to the need for this infrastructure, these assays are inappropriate for use in resource-poor settings [98] .

Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is an alternative approach to the traditional RT-PCR method. Compared with the other amplification methods, the LAMP methodology is faster and the whole process takes place at a constant temperature. Such an innovative technique uses two important features to decrease reaction time: a polymerase with displacement activity and a set of 4 to 6 primers designed to create loop structures in the template containing primer annealing sites for amplification. The effect is an amplification product (amplicon) identified by color, turbidity or fluorescence detection in a few minutes. Besides shorter reaction time, the assay can occur in simple devices, some of them developed to be used in no power condition, as battery-coupled machines or fast colorimetric tests, revealing a sensitive and easy-to-use potential for point-of-care diagnosis [98] . These features J o u r n a l P r e -p r o o f make the LAMP assay an appropriate detection tool for outbreaks of emerging and reemerging diseases [99] .

However, although RT-LAMP presents advantages compared to conventional RT-PCR, it has some intrinsic limitations, such as a complex pre-study to select the better-conserved target gene region and the design of more efficient primer sets. In addition, the RT-LAMP can present false-positive results during its post-amplification process, characterized by the PCR inhibition internal control, which can lead to nonspecific amplification products [100] [101] [102] .

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas-based assay) is a sophisticated technique of gene-editing that has revolutionized the molecular biology field. CRISPR is an important bacterial defense mechanism against an invading genome, characterized by small nucleic acid sequences repeated throughout the bacterium genome. There is a "nucleic acid spacer," called Protospacer Adjacent Motif (PAM), between each short palindromic sequence. PAM is a short non-coding sequence, which indicates the cleavage site for an enzyme known as Cas. Then, the CRISPR sequence is transcribed in small RNA fragments (crRNA or guide-RNA), which have the ability to annealing with foreign DNA. The guide-RNA (gRNA) orients the Cas enzyme until cleavage site, and next, the invading genome is eliminated [103] .

Although numerous Cas enzyme types exist, only those with nuclease activity, such as Cas-12 and Cas-13, are used for diagnosis. Furthermore, for the CRISPR/Cas system to be used as a detection tool, the gRNA must be genetically modified to bind a specific target sequence. After, the cleaved fragments link to a fluorescent probe to be quantified by fluorescence spectroscopy [104] . Some reports show that when this system is associated with a pre-amplification method, there is a sensitivity improvement of the assay, allowing the detection of deficient levels of concentration of target [105] . Therefore, the recent viral spread of SARS-CoV-2 has led to numerous adaptations of CRISPR/Cas systems for COVID-19 diagnosis.

Broughton et al. [106] reported developing a CRISPR-Cas12-based assay, In summary, the CRISPR/Cas system has shown be promise technology for diagnosing various diseases [109] [110] [111] . However, there are still many caveats related to this technique. Among them, it is possible to highlight: (i) the need for a professional with experience in protein purification and in molecular biology techniques for that all reaction components are made and used correctly; (ii) difficulties in obtaining predesigned kits (reaction components); (iii) decreased sensitivity and specificity of the assay when using the pre-made kits; and (iv) all the disadvantages (pre-mentioned) related to the amplification assays [103, 105] .

Immunoassays are also approaches used in the frontline testing for specific diagnoses of COVID-19. These assays can provide information on whether a person was infected recently (active viral infection) or in the past [112] .

After one year and a half of SARS-CoV-2 discovery, there are still several gaps to be understood about the immune response against the viruses. Some studies related S and N viral proteins as primarily responsible for inducing immune response [113] . N protein has shown to be more immunogenic among HCoV proteins, but it induces antibodies with a shorter duration than ones against S protein. Studies have reported that S protein antibodies can be viable 11 years after patient exposition to some HCoV type [114] . Such findings make S protein the target of choice for studies related to the production of vaccines [29] .

SAR-CoV-2 immune memory is not yet fully understood. Some cases reported have suggested a short timeframe, around four months, between recovery and possible reinfection in the same person [62] . Therefore, WHO and CDC have emphasized that immunodiagnostic tests should be used in cases of evaluating the infection progression, epidemiological screening, and in the research environment [115] .

The main immunological tests used for diagnosing SARS-CoV-2 infection include neutralization antibody (NA), rapid diagnostic test (RDT), chemiluminescence immunoassay (CLIA), and enzyme-linked immunosorbent assay (ELISA) [116] .

In NA assay, the patient's sample is added to a cell culture medium and incubated for 3 to 5 days. The functional ability of antibodies against SARS-CoV-2 is then determined. Although more specific and accurate, NA assay requests a long period and biosafety certificates laboratories (BSL2 or BSL3), making them impracticable for rapid tests [116] .

RDT is a simple, fast, and inexpensive test based on the lateral flow immunoassay (LFIA) method to detect specific antibodies (IgG, IgM, or IgA) of SARS-CoV-2. In this technique, a drop of a patient's sample (whole blood, serum, or plasma) is spilled on a disc strip, where the reaction occurs. The result is released on average 20 min later, presenting the potential to be used as point-of-care tests. However, this method has shown poor accuracy, less than 20% compared to ELISA, causing a high rate of false-negative results [117] .

CLIA is a method that combines chemiluminescence with immunoreaction (antibody-antigen interaction). When the target recognizes and interacts with a receptor linked to a luminescent molecule (luminol, acridine, and their derivatives), such a molecule is released. It returns to its fundamental state, emitting light [118] . The intensity of light emitted has a linear relationship with the concentration of the measured substance [119] , with an average time-to-result of 1 to 2 h [116] .

J o u r n a l P r e -p r o o f ELISA is the most common immunodiagnostic method. This assay has a similar concept to the CLIA. Immunoreaction is also associated with light emission from a chromogenic agent released in the reaction, and the intensity of emitted light corresponds to the target concentration in the sample [120] .

ELISA is robust and easy to perform regarding immunoassays. Nevertheless, for SARS-CoV-2, these tests have low sensitivity and specificity when compared with antibody detection of other infection agents. These caveats are related to the unclear SARS-CoV-2 antigens definition for antibody detection; or usage of different targets for antibodies, as S protein, N protein, or both; or cross-reaction with other HCoVs antigens (high antigenic homology), and dependence on antibody production kinetics [112, [121] [122] [123] ].

Blood routine tests can complement diagnosis. Some reports identify alterations in blood components suggestive of early SARS-CoV-2 infection, as lymphocyte count reduction and an increase of serum amyloid A (SAA), C-reactive protein (CRP), and erythrocyte sedimentation rate.In severe cases, an increase in the rates of creatine kinase (CK), lactate dehydrogenase (LDH), and aspartate transaminase (AST) can be detected [124] . Because these alterations can be associated with other viral infections, specialists should interpret results with caution. In cases of doubt, a more specific test, as RT-PCR, is recommended. SARS-CoV-2 causes typical pulmonary alterations in most COVID-19 patients, such as ground-glass opacities, multifocal patchy consolidation, or interstitial changes with a peripheral distribution. These abnormalities are not specific to COVID-19 since they exist in other pathologies [125] . Nevertheless, CCT has played a crucial role in symptomatic patients with negative RT-PCR, helping diagnosis by images alterations, clinical and laboratory evidence, and information if the patient had contact with a patient diagnosed with COVID-19 [97] .

The global scientific community has come together to improve existing assays and develop new ones that can help understand the pathogenesis and epidemiology of SARS-CoV-2, and expand the diagnostic assays for this virus and thus contribute to the pandemic end. However, despite all the worldwide aid, there are still several challenges J o u r n a l P r e -p r o o f to achieving an excellent diagnosis performance (effective and accurate SARS-CoV-2 detection) (Fig.3A/B ). Among them, can be a highlight: (i) non-specific symptoms, which may be confused with other diseases; (ii) high correlation phylogenetic and immunologic with other coronavirus species, which may cause false-positive results and (iii) overload of diagnostic capacity, causing delays in the patient samples analysis [16, 40, 65, 97] .

Proper sample collection is essential for an effective diagnosis of infectious diseases. According to WHO [126] , the ideal samples for genetic detection of SARS- suggested were to be improved in all approach types, including rapid communication between agencies and countries to avoid, control, and reduce the impact caused to society [127] .

As highlighted at the meeting, it is imperative to emphasize that a quick and effective diagnosis is crucial to mitigate the disease outbreaks effect. Recent outbreaks reinforce the need to use a point-of-care (POC) approach to control the disease epidemic. A study made by Kost et al. [128] and Perkins and co-workers [129] After implementing collaborative data support between academia and industry was possible to observe the rapid development of new diagnostic tools, drugs, and vaccines against COVID-19 [16] . This connection takes us to the definition of translational medicine (MT), an area that is currently expanding. MT presents an interconnected approach, covering each stage of the research to the commercialization of the final product, which streamlines the entire process, benefiting the population [130] .

Thereby, diagnostic technology investments could provide the health system with new approaches, as high-performance tools, which present fast response, high specificity and sensitivity in detection, ease of use, low cost, portability, and PCR-free (Fig.3B ). With such improvement approaches, we would probably be able to achieve the ideal scenario for pandemic control.

A crucial step for SARS-CoV-2 diagnosis was the fast sequencing of the entire genome and its availability in public databases by Chinese. Genome analysis is considered the main form to find specific biomarkers for infectious disease detection.

Biomarkers are molecular signatures associated with the presence, severity, or disease type necessary for diagnostic, prognosis, monitoring, and therapy.

Multi-omics analysis (genomics, transcriptomics, proteomics, and metabolomics) has proved to be a robust approach to identify several molecular signatures associated with COVID-19 [131] . Such approaches provide a holistic molecular perspective of biological systems compared to traditional analysis. For SARS-CoV-2 (Fig. 4) , omics studies have revealed deregulations of some inflammatory factors, metabolites, and other molecules found in blood, including amino acids, carbohydrates, fatty acids, and glycerophospholipids [132] .

Zang et al. [133] analyzed 140 samples from positive RT-PCR patients for SARS-CoV-2 and observed a positive correlation between decreasing in blood eosinophil and lymphocyte with the severity of the disease. Messner et al. [134] analyzed other 188 serum samples. They found 27 potential biomarkers (complement factors, the coagulation system, inflammation modulators, and pro-inflammatory factors) differentially expressed depending on the COVID-19 severity grade. Among these classes of biomarkers, the interleukin 6 (IL-6) was more elevated in severe disease presence. The IL-6 is associated with inflammatory cascade and, consequently, presents an essential role in the host immune modulation. So, IL-6 can be a relevant predictive biomarker of the SARS-CoV infection progression [135] .

Ellinghaus et al. [136] analyzed 3815 samples from Italy and Spain patients (1610 positive samples and 2205 controls). They performed a genome-wide association study (GWAS), which associates specific genetic variations with particular diseases [137] . In total, they analyzed 8,582,968 single-nucleotide polymorphisms (SNP) common to both countries. The results show two independent gene variants associated with the severe form of COVID-19, rs657152 (A or C SNP) at locus 9q34.2 and rs11385942 (insertion-deletion GA or G variant) at locus 3p21.31. The 9q34.2 locus is responsible for encoding ABO antigen erythrocyte proteins. According to the analysis, patients with blood group A present a higher risk of developing severe COVID-19 than any other blood group. However, the 3p21.31 locus contains genes that encode chemokines, whose function is to attract immune cells to infection sites. Modification in these genes can lead to an increase in the immune response. Furthermore, the SLC6A20 gene, also present in the locus, encodes neuronal norepinephrine transporter (NET) that interacts with ACE2, the SARS-CoV-2 cell-surface receptor [138, 139] . Polymorphisms in this gene have been associated with neurological and blood pressure disorders [125] , leading to higher susceptibility to severe forms of Covid-19 [140, 141] . and IL-10. IL-6 detection indicates worsening of the patient's condition [132] .

In summary, multi-omics approaches can allow a complete view of COVID-19 pathophysiology [145] . Additionally, such analysis can aid in the discovery of the molecular signature, which may be present or altered by the SARS-CoV-2 infection [146] . These assays have great importance for the advance of both precision and personalized medicine [131, 147] . Most biomarkers discovered for COVID-19 are not specific for only SARS-CoV-2 infections but can be helpful in the prognostic, severity, and monitoring of COVID-19 [132, 146] . In addition, biomarkers can be deposited in a network database and connected to epidemic mathematical models, generating algorithms capable of predicting, controlling, and preventing infectious disease outbreaks and a pandemic [132, 148] .

Several regions of the world have a flawed health care system. Various patients waited a long time to be assisted by a health professional, and obtain the test results requested by him, generating a high risk of death for the patient. Early detection and reporting to health authorities are the first steps for an effective infectious disease outbreak response.

In primary healthcare, fast and specific disease detection is fundamental, allowing an early diagnosis and accurate epidemiological surveillance. The increasing number of research and commercially available point-of-care tests (POCTs) are crucial to respond quickly and effectively to infectious disease outbreaks, and consequently, minimize the spread of pathogens, reducing the number of infected persons [149] .

Point-of-care (POC) analyses are tests performed at or near the patient's site (at the health care system or home). The main characteristics of these tests are simplicity, quick results, user-friendly, low cost, and ability to perform outside a laboratory ( Fig.3 .B) [16] .

POCT is in evidence, gaining more importance for both health and economic systems. They can be essential in resource-limited locations where health care, transportation, and infrastructure are precarious. These tests allow for diagnostic evaluation without the reliance on laboratory infrastructure, averts the requirement for sample transport, and reduces processing times [150] . Thus, it could be possible to expand quickly and efficiently access to diagnosis. In addition, they could offer benefits such as easy execution in the field and results of simple interpretation, which can generate significant gains for health resources [16, 149] .

Considering an ideal scenario for SARS-CoV-2 pandemic control would be needed: (i) early identification of positive cases in the field, even in remote locations;

(ii) efficient sample collection; (iii) protective measures implementing for both patient and health professional; (iv) antibodies detecting in early and after infection; and (v) effective vaccine development and a fast vaccination for all population [97, 151] .

The ideal type of sample collection (swabs in the region of the upper airways), as well as RT-PCR, were the methods of choice for diagnosis according to WHO, limiting the use of POCT approaches [16, 152] (Fig.3) . Nevertheless, many studies focus on improving the actual POCTs available and developing new POC approaches as biosensors [153] .

Grand View Research, Inc., a USA-based market research and consulting company, reports a high investment forecast for the diagnostic sector, expected to reach $ 43 billion by 2029. Regarding the diagnosis by POCT, this will grow by $ 27.66 billion in 2020, with a prospective compound annual growth rate (CAGR) of 3.25% until 2028 [154] .

The market drives the development of this test type due to the growing increase in chronic diseases (diabetes, cardiac diseases, cancer) together with the increased proliferation of infectious diseases (HIV, syphilis, arboviruses, tuberculosis). However, the recent pandemic associated with SARS-CoV-2 accelerated the POCT development.

The market growth is due to the high demand for small diagnostic devices, rapid technological advancements, and the increasing scope of application devices in the medical field [152, 155, 156] .

One crucial point for an effective diagnosis of COVID-19 is the appropriate nasopharyngeal or oropharyngeal swab sample collection from patients. The inconvenience is that such a collection method is invasive [157] and may cause significant discomfort to patients, leading to an incorrect collection, especially in children. Other disadvantages are: decreasing of patient consenting to a retest, if necessary, because of discomfort; induction of sneezing and coughing, facilitating the viral particles transmission through the air and a risk for health professionals involved in sample collection [158] ; needing of trained personnel for collection, applying, rigorously, CDC guidelines [159] ; needing of sterile swabs, which has caused a tremendous worldwide demand for this material [16] .

Accurate and non-invasive samples for SARS-CoV-2 detection could facilitate effective large-scale pandemic control measures to prevent the COVID-19 spread.

Health agencies have expanded the list of types of samples used for the SARS-CoV-2 RNA detection; among them are nasal, sputum, blood, urine, feces, and saliva samples [159, 160] .

Many studies focus on finding ways to collect patient samples in a less invasive manner. Although sample sputum is a non-invasive method for lower respiratory tract sample collection, many patients, mainly children, cannot perform the sputum procedure [161] . Research has shown that the use of oral/saliva fluids to detect SARS-CoV-2 offers several advantages over nasal/oropharyngeal samples [161, 162] . Saliva J o u r n a l P r e -p r o o f can be easily collected, as it is only necessary to spit into a sterile tube. In addition, saliva collection does not require certification as it does for swab collections; also, it does not require specific transport or a trained professional to carry out the collection.

Another important point is that the saliva collection procedure does not generate aerosol, which decreases the safety of health professionals, reducing the risk of transmission [161] . There was a high overall agreement (96.1%) between the two tests (swab and saliva).

Yamazaki e co-workers [164] developed a triplex RT-LAMP from saliva samples. The results show that this approach had a sensitivity of 82.6% (19/23) and a specificity of 100% (21/21), compared to the reference standard. The limit of detection was 250 copies/reaction (25,000 copies/mL).

Several studies suggest that saliva samples for detecting of SARS-CoV-2 can be an excellent alternative for improving of POC diagnosis. However, more accurate studies about its analytical performance are needed to improve its specificity and sensitivity [165, 166] (Fig.3B ).

Biosensors are analytic devices increasingly explored as simple and promising diagnostic tools able to differentiate more than one disease in a single sample [167] .

Besides that, it can be a quick and inexpensive alternative to conventional analytical measures, such as detection and monitoring of chemical and biochemical substances, infectious agents, and biomarkers applied to clinical diagnosis [168] [169] [170] [171] . Such devices are portable and accurate diagnostic tools, that can be miniaturized and used in remote areas without well-trained professionals.

In the '60s, Leland C. Clark developed the first enzymatic biosensor. He immobilized the glucose oxidase on a platinum electrode and observed that the presence of glucose in the medium decreased the glucose and oxygen concentrations, proportionally to the increasing of hydrogen peroxide concentration [172, 173] Today, it is possible to apply biosensors in several fields, such as the food industry, environment control, forensic analysis, military defense, medical field, and others [174] . Among these, the medical field has stood out because of its potential to be J o u r n a l P r e -p r o o f used as detection/mensuration tools in personalized medicine (PM) [175, 176] . PM is the personal molecular data used to help determine whether a person has predisposing factors (expressed or overexpressed biomolecules) for a particular disease [176] .

Another good point is the possibility of integrating biosensors to the IoT (Internet of things) and AI (artificial intelligence). Thus, test results can be displayed on mobiles and automatically transmitted by several wireless network modalities (e.g., cellular data service, Wi-Fi, Bluetooth) for a cloud heath database [177] [178] [179] .

Due to the SARS-CoV-2 pandemic, global health authorities are looking for effective ways to control the COVID-19 outbreak through improvements in the diagnosis and monitoring of the virus. Thus, the advances achieved with portable diagnostic tools, such as biosensors, which demonstrate the ability to analyze samples and automatically send the results to the physician and a database network, allow a significant advance in global health management [152, 177, 180] .

According to the report published in June 2020 by the ReportLiker Company, the global biosensor investment market is expected to grow, even taking into account the harmful effects of the pandemic on the economy, $ 36,630.29 million by the end of 2025 at a compound annual growth rate (CAGR) of 8.91%. This growth was due to the worldwide need for efficient diagnostic tools, whose main principle has rapid analysis, high accuracy in results, autonomy, and connectivity to health systems [181] .

Biosensors are devices that combine immobilized biomolecules (nucleic acids, antigens, antibodies, tissues, cells, among others) to a transducer, creating a surface that allows the qualitative and quantitative measurement of a specific analyte [182] . The specific interaction between the target and the biological recognition element (bioreceptor) results in a biological signal detected by a transducer. The biological signal is converted, in real-time, to an electric signal proportional to the target concentration [182, 183] (Fig.4) .

Biosensors are classified according to the biological recognition element (bioreceptor) or the signal transduction mode (electrochemical, optical, piezoelectric, calorimetric, and other) [152, 182] .

Electrochemical is the most used among diverse transduction types due to their portability, low cost, effectiveness, easily miniaturized, simple instrumentation, and sample turbidity independence, which permit the specific target detection in complex samples, such as biological samples [184] . Besides, electrochemical analyses have shown better performances in comparison to other assays types [185] .

The target molecules used for detecting viral agents in the samples can be of various types, for example, the viral nucleic acid, a specific viral protein, antibodies, or some specific biomarker found by multi-omic analysis. Thus, a biosensing platform developed for SARS-CoV-2 virus diagnosis can be classified, according to the IUPAC [182] , as a genosensor, immunosensor, or aptasensor platform (depending on biorecognition element used to detect the target) [145, 147, 182, 183, 186, 187] Genosensors and immunosensors are biosensors devices with biological recognition element, a known nucleic acid sequence (probe), and an antibody or antibody fragment, respectively [188, 189] . Classically, the basic immunosensor principle detects the interaction between an antibody and its antigen [190] . At the same time, the genosensor, the target recognition, is done by hybridization event, whose target-sequence of the gene is identified by a probe, forming a hybrid [191] .

However, genosensors can also use as a recognition element, a special oligonucleotide that exhibits a three-dimensional conformation. This structure is known as aptamer [192] . Aptamers are short DNA or RNA oligonucleotide sequences (10-100 nucleotides), which are artificially synthesized by in vitro technology known as Systematic Evolution of Ligands by Exponential Enrichment (SELEX) [193] .

Aptamers are excellent receptors because they bind with high affinity and specificity to various targets, such as viruses, cells, proteins, peptides, and small organics molecules [194] . Aptamers bind their target with an affinity similar to or higher than antibodies. This interaction occurs via an induced-fit mechanism involving van der Waals forces, electrostatic interactions, and hydrogen bonding [195] . Therefore, aptamers work similarly to synthetic or chemical antibodies. In addition, aptamers offer more attractive features compared to antibodies [196] . They have a less expensive production process since they use in vitro synthesis (avoiding animal experimentation), are easily modifiable with functional groups (facilitating immobilization process), and are highly stable (providing the long-term storage) [194] .

Electrochemical biosensors for virus detection using different bioreceptor types, but no amplification approaches (PCR-Free) have been developed [168, 170, [197] [198] [199] .

J o u r n a l P r e -p r o o f Table 2 shows biosensors for detecting different virus types, presenting high sensitivity, specificity, and low detection. So, the biosensing platforms developed to detect SARS-CoV-2 can be a promising alternative for COVID-19 point-of-care diagnosis and a safe tool for the health professionals.

Li et al. [200] described the development of a rapid and PCR-free biosensing platform for SARS-CoV-2 RdRp gene detection in human throat swab specimens. The bioreceptor used for viral RNA recognition was a phosphorodiamidate morpholino oligos (PMO), a class of uncharged DNA analogs [201] . These oligos are a promising recognition element for genosensor development since they do not have charges, decreasing the background signal and allowing an ultrasensitive DNA detection [202] .

Li and co-workers immobilized the PMO-probe on a graphene-based field-effect transistor (G-FET) surface, pre-modified with AuNP (Gold nanoparticle). The platform presented a low limit of detection in PBS (0.37 fM), throat swab (2.29 fM), and serum (3.99 fM), as well as it managed to differentiate the RdRp genes present in SARS-CoV-2 and SARS-CoV.

Although the biosensing platforms are very sensible and specific, some features in platform build can be crucial for high performance and reproducibility.

Most electrochemical transducers are composed of three electrodes (Fig.5) : (i) a reference electrode (RE) to maintain a stable reference potential; (ii) an auxiliary electrode (AE), to protect the reference electrode from the electrolysis process; (iii) a working electrode (WE), the place where the bioreceptors are immobilized [203] .

Bioreceptors and target binding occur on the WE surface, representing an essential component of the platform. It is responsible for converting the biological signal generated by the bioreceptor-target integration into a measurable signal [204] .

There are many types of WE available -mercury, platinum, silver, gold, carbon, indium tin oxide (ITO)and, due to its relevant role in sensing platform, the type choice is crucial to analytical performance [204, 205] . Therefore, the material of WE must not interfere in the electrochemical reaction, allowing an efficient and selective transduction pathway [206] .

Despite the wide range of working electrode diversity, carbon-based electrodes are the ones that draw the most attention [207] . Carbon is a chemically inert material, beyond presents good electrical conductivity, wide potential range, low background current, low cost, and high reproducibility, advantageous features of an electrochemical component candidate [205, 208] .

Many studies focus on the search and characterize chemical agents (modifying agents), which can produce thin films on the WE surface to support target immobilization and improve the transducer's analytical performance [183] . The film's structure, composition, and functionalities determine the modified electrode performance (Fig.5) .

The behavior film depends on the methodology used to coat the electrode surface since the more uniformly the film is, the higher its analytical performance is.

Electrochemical polymerization (electropolymerization) is a versatile assay that synthesizes the thin-film coating of different materials onto several surfaces. The electropolymerization procedure is one of the most promising electrode modification methods compared to other approaches, once, all film coating processes (film growth) can be monitored [209, 210] .

Electrochemical techniques used for film growth can be galvanostatic (chronopotentiometry), potentiostatic (chronoamperometry), and potentiodynamic (cyclic voltammetry -CV) [211] . CV is performed by cycles using a potential range from negative to positive, back and forward. When potential is applied, monomers polymerize, forming the film onto the WE surface [212, 213] .

A critical step in the development of a biosensing platform is the immobilization of the recognition element. Most receptor molecules are susceptible to the environment and can quickly lose their viability. Polymeric films can stabilize the system, exposing free functional groups to orient the binding process of the bioreceptor on the WE surface [214] . Several mechanisms can immobilize biomolecules on sensors, such as adsorption, covalent bonding, and avidin-biotin interaction [215] . However, an efficient immobilization process requires controlling factors like orientation, density, distribution, and movement freedom of molecules [183] . Among the immobilization J o u r n a l P r e -p r o o f techniques cited above, covalent bonding can form stable complexes between the functional groups of the polymeric film and the immobilized molecule [216] .

WE properties, such as material type, surface modification, surface area, and immobilization method employed, are extremely important for developing a biosensor since an inadequate immobilization can cause loss of activity, less specificity, and low biocompatibility of the biomolecule, impairing the analytical performance of the biosensor. Research has focused on joining various technologies, such as nanomaterial, nanotechnology, and nanoengineering, on generating biocompatible interfaces with more stability and sensitivity, improving the basis for new analytical devices for biomedical fields [185, [217] [218] [219] .

According to European Commission (2011), nanomaterial is defined as "a natural, incidental, or manufactured material containing particles, in an unbound state or as an aggregate and where, for 50% or more of the particles in the number size distribution, one or more external dimensions is in the size range 1 nm -100 nm". In specific cases and when warranted by concerns for the environment, health, safety or competitiveness, the number size distribution threshold of 50 % may be replaced by a threshold between 1 and 50 %" [220] . Moreover, it exhibits other characteristics such as high strength, elevated chemical reactivity, and high conductivity [221] . A wide range of nanomaterials is available in the literature, including as gold nanoparticles, carbon nanotubes, graphene, photonic crystals, silica nanoparticles, nanowire, indium tin oxide, metallic, quantum dots, polymer nanoparticles, magnetic nanoparticles or magnetic beads (MBs), and other [222] .

Advances in nanotechnology have permitted new strategies to improve WE modification [221] . Nanomaterials have interesting physicochemical properties, such as excellent electrical and catalytic properties and many adsorption-active sites [223] .

These features improve the coating process onto electrodes, and leave important functional groups available, which raise the stability of the bioreceptor immobilization [224] . Thus, advances in nanotechnology have permitted new strategies to advance WE modification [225] further. The study numbers about sensor devices using modified WE by conductive nanomaterials have increased, leading these devices to ultra-low limit detection of the target [213, 226] .

The nano matrices provide an increased surface area of the WE, enabling a more significant number of bioreceptors units immobilized [227] . Furthermore, these matrices can accelerate charge transfer, resulting in a synergic influence (more bioreceptor and high conductivity), providing signal amplification [225, 228] . Thus, it is evident that these matrices used on the WE lead to enhanced biosensor performances with increased sensitivity and limited detection with a deficient order of magnitude (Table 2 ).

In the last decade, nanopores were coupled to sensor systems, further increasing these tools' capacity to detect and quantify the specific targets in ultra-low concentrations, reaching at the femtomolar (fM) level [229, 230] . Nanopores devices have as a principle the entry of one molecule at a time, that is, in a unitary manner. The size of the nanopore channel is based on the molecule to be detected, serving as a filter.

However, detection is usually unsatisfactory when the target molecule has minor differences in shape and size with other molecules present in the sample. Such drawbacks can be improved by combining specific bioreceptors with nanopores. In these cases, the nanopores became working electrodes, going through a chemistry modification process and then immobilizing the recognized element [231] . In nanopore devices, the potential application causes a flow of molecules that directs the target to the entrance of the nanopore channels [232] . The chemical (target-bioreceptor interaction into the nanopore) to electrical signal transduction can directly interfacing with electronic devices [233] . Nanopore electrode systems are emerging as a new class of biosensors with high potential to be integrated with point-of-care devices, identifying a range of biomarkers related to human health and wellness [234] .

Rai et al. [235] developed an ultrasensitive electrochemical genosensor for detecting dengue virus type 1 using a nanopore-based membrane. In that work, an alumina film using anodizing technique coated the platinum electrode (workingelectrode). In this technique, the metal to be coated goes through an electrochemical oxidation process, producing an anodic oxide layer on the electrode surface. Its objective is to increase the conductivity and extend the limit of target detection in the electrochemical analysis. Following the anodization process, the specific probe for the DENV-1 genome was immobilized on the alumina channel walls. This platform presented a range of detection from 10 −12 to 10 −6 M and a limit of detection (LoD) of 9.55 pM.

Shariati et al. [236] combined the conductive properties of nanomaterials with nanopores to achieve a detection limit in a concentration lower than picomolar (pM).

They developed a genosensor for HPV16 using gold nanotubes (AuNTs) based on nanopores polycarbonate (NPC) in an electrical alignment. NPC, used as a working electrode, was functionalized with AuNTs, followed by probe immobilization. When the external electric field was applied, the target DNA (HPV16) entered the nanopore.

This genosensor manufactured under electric field amplification detected low target concentrations (0.01 pM to 1 µM) and presented a LoD of 1fM.

Mojsoska et al. [237] described the first optimization steps of a label-free electrochemical immunosensor using graphene-modified WE for the S protein detection of SARS-CoV-2. This biosensor was able to detect S1 of recombinant S protein at 260 nM (20 µg/mL) of subunit 1 of recombinant spike protein, as well as to detect SARS-CoV-2 at 5.5 × 105 PFU/mL.

Mahari et al. [238] developed a homing-made electrochemical immunosensor device, eCovSens, using screen-printed carbon electrodes (SPCE). This device made it possible to detect the S protein antigen of SARS-CoV-2 in saliva samples with LoD at 10 fM within 10-30 s.

Lab on Chip is a device that integrates traditional analytic methods traditional of a laboratory in a single and miniaturized microprocessor (microchip), using the microfluidic technology to manipulate low volumes (10 -9 to 10 -18 L) of complex fluids [239] .

The central Lab on Chip characteristics coupled in the biosensor is precise fluid flow control under laminar conditions, low volumes of samples and reagents; sample mix, separation and detection of the molecules present in the sample; short analysis time; better control process in all analysis stages; high-throughput analysis (high resolution and sensitivity); multiplex analysis; low-power operation; and better production cost-effectiveness. In addition, the entire analytic process is automated into the chip, preventing loss and contamination of samples and substantially reducing analytical errors. These features provide this device more advantageous than traditional electrochemical biosensing platforms, such as high throughput, efficient performance metrics; higher sensitivity and specificity; shorter detection time, and a lower detection limit. So, it has attracted much attention because it can provide a significant improvement in POCT [240] . 

is widely explored in the health area. The fusion of these technologies with sensing devices significantly impact on the health system, mainly facilitating access to people living in remote areas [177] . In addition, data generated could help create a data platform with information that associates symptoms, epidemiologists, diagnosis, risk factors, medical history, and changes in laboratory tests. These patients' information databases connected to a Machine Learning (ML), "computers that automatically learn certain tasks through experiments," making this approach a powerful tool to aid medical diagnosis and decreasing error rate in diagnostics (Fig.3B) [178, 242] .

Every day, we can easily use applications (apps) obtained from online stores offered on smartphones that offer resources where the users describe their data associated with symptoms. Automatically, these tools analyze the data (through mathematical models), considering age, pre-existing diseases, if they reside in endemic areas, symptomatology, and other factors. Based on such data collection, apps can calculate the possibility that a person is sick and guide them to seek medical care, if necessary, indicating the health center closest to their residence. Additionally, apps can provide information to the competent authorities on the epidemiological situation of a given region [243] .

AI and IoT technologies can integrate into remote sensing systems in drones. As an example, we can mention a task force carried out in Malawi (Africa) in 2017. This country had a cholera outbreak with a high death rate associated with the infection. So, the United Nations Children's Fund (UNICEF) led a group of physicians, technicians, J o u r n a l P r e -p r o o f and researchers to help people affected by cholera. The group used drones associated with sensors, which could detect contaminated water by remote sensing [244] .

In this context, tremendous impact that the combination of IoMT, AI, and embedded systems with biosensing platforms can bring to the global health system management and logistics is clear. It means that a powerful diagnostic system based on POC and PM can be developed and used to mitigate the infectious disease outbreaks effects in the world [245, 246] .

Researchers from all over the world came together to discover the fundamental factors related to SARS-CoV-2, such as origin, evolution, transmissibility, and virulence, through complete studies, including omics analyzes. In addition, there is a race for the improvement of standard diagnostic tests, and for the development of new technologies, such as biosensing platforms.

The biosensors can monitor viral spread in real-time, promoting more accurate and faster diagnostic solutions. Moreover, biosensors integrated with IoMT can connect and remote monitor patients, decreasing health staff exposure.

The importance of investment in science and technology for developing innovative ways to deal with tragedies as Covid-19 pandemics is urgent, mainly in developing countries. More than ever, science is the tool for developing diagnosis strategies, therapies, and vaccines. Public authorities, thinking in general health and the common good, should base their decisions on science and educate their population, leading to good practices, health security and the pandemic's end.

Thus, this review shows us a variety of challenges that we still have to overcome to achieve an ideal scenario both for controlling the current COVID-19 pandemic and preventing the new pandemic outbreaks.

The authors declare no competing interests. 

Infectious diseases and Neolithic transformations: Evaluating biological and archaeological proxies in the German loess zone between 5500 and 2500 BCE

Emergence and Spread of Basal Lineages of Yersinia pestis during the Neolithic Decline

Psychiatry of Pandemics

The history of plague -Part 1. The three great pandemics

Review on Principles of Zoonoses Prevention, Control and Eradication

Emerging Pandemic Diseases: How We Got to COVID-19

Emerging infections-an increasingly important topic: review by the Emerging Infections Task Force

Implications of human activities for (re)emerging infectious diseases, including COVID-19

Host Diversity and Origin of Zoonoses: The Ancient and the New, Animals. 10 (2020) 1672

Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review

Key Strategies to Address Emerging and Reemerging Infectious Diseases: A Systematic Analysis

Are we there yet? The transition from response to recovery for the COVID-19 pandemic

Pandemic Reemergence and Four Waves of Excess Mortality Coinciding With the 1918 Influenza Pandemic in Michigan: Insights for COVID-19

Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review

COVID-19-A Novel Zoonotic Disease: A Review of the Disease, the Virus, and Public Health Measures

Considerations for diagnostic COVID-19 tests

Testing at scale during the COVID-19 pandemic

COVID-19 vaccines: where we stand and challenges ahead

SARS-CoV-2 Variants and Vaccines

Molecular Evolution of Human Coronavirus Genomes

Coronaviruses: An Overview of Their Replication and Pathogenesis

Genotype and phenotype of COVID-19: Their roles in pathogenesis

Genotyping coronavirus SARS-CoV-2: methods and implications

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Structure of replicating SARS-CoV-2 polymerase

An in vivo cell-based assay for investigating the specific interaction between the SARS-CoV N-protein and its viral RNA packaging sequence

Structure of the SARS Coronavirus Nucleocapsid Protein RNAbinding Dimerization Domain Suggests a Mechanism for Helical Packaging of Viral RNA

Viral targets for vaccines against COVID-19

The evolution of RNA viruses: A population genetics view

Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity?

Fields Virol

A New Virus Isolated from the Human Respiratory Tract

SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far, Pathogens

SARS and MERS: Recent insights into emerging coronaviruses

SARS, the First Pandemic of the 21st Century

The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

Middle East respiratory syndrome coronavirus (MERS-CoV) -Saudi Arabia -Updated

Genomic sequencing of SARS-CoV-2:a guide to implementation for maximum impact on public health., Geneva: World Health Organization

Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV

Coronavirus (COVID-19) Dashboard With Vaccination Data, World Heal

Pre-fusion structure of a human coronavirus spike protein

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Proteasemediated enhancement of severe acute respiratory syndrome coronavirus infection

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Severe COVID-19: A Review of Recent Progress With a Look Toward the Future

Structure of Furin Protease Binding to SARS-CoV-2 Spike Glycoprotein and Implications for Potential Targets and Virulence

Structural basis of receptor recognition by SARS-CoV-2

SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments -Updated

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Temporal profile and determinants of viral shedding and of viral clearance confirmation on nasopharyngeal swabs from SARS-CoV-2-positive subjects: a population-based prospective cohort study in Reggio Emilia

Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon

Prolonged shedding of severe acute respiratory syndrome coronavirus 2 in patients with COVID-19

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Interim Guidelines for COVID-19 Antibody Testing -Updated

Patterns of IgG and IgM antibody response in COVID-19 patients

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

Serum IgA, IgM, and IgG responses in COVID-19

Understanding protection from SARS-CoV-2 by studying reinfection

Genomic evidence for reinfection with SARS-CoV-2: a case study

Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor

Clinical management Clinical management : Living guidance COVID-19

Why Do COVID-19 Fatality Rates Differ Across Countries? An Explorative Cross-country Study Based on Select Indicators, Glob

Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries

Notable Variants of SARS-CoV-2

Genetic Variants of SARS-CoV-2-What Do They Mean?

The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types

CoV-2 Variant Classifications and Definitions -Updated

CDC, SARS-CoV-2 Variant Classifications and Definitions: Updated

SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility -Oklahoma

SARS-CoV-2 variants of concern are emerging in India

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?

Delta plus: Scientists say too early to tell risk of Covid-19 variant

Nova variante Delta Plus é mais perigosa do que as outras? Veja o que se sabe

SARS-CoV-2 variants of concern and variants under investigation in England -Technical briefing 19

The molecular basis for SARS-CoV-2 binding to dog ACE2

Identifying Primate ACE2 Variants That Confer Resistance to SARS-CoV-2

The SARS-CoV-2 S1 spike protein mutation N501Y alters the protein interactions with both hACE2 and human derived antibody: A Free energy of perturbation study

Diagnosing COVID-19: The Disease and Tools for Detection

Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection

Interpreting a covid-19 test result

Antibody responses to SARS-CoV-2 in patients with COVID-19

Use of chest imaging in COVID-19: a rapid advice guia., World Health Organization

Imaging findings in COVID-19 pneumonia

COVID-19 pneumonia: A review of typical CT findings and differential diagnosis

COVID-19: molecular diagnostics overview

Real-Time RT-PCR Diagnostic Panel For Emergency Use Only

Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)

Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based J o u r n a l P r e -p r o o f SARS-CoV-2 Tests by Time Since Exposure

Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient

False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications

Molecular Diagnosis of COVID-19: Challenges and Research Needs

Assay Techniques and Test Development for COVID-19 Diagnosis

Recent progress in RT-LAMP enabled COVID-19 detection

Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19

Loop-mediated isothermal amplification (LAMP)-review and classification of methods for sequence-specific detection

Loop-mediated isothermal amplification (LAMP): a versatile technique for detection of microorganisms

CRISPR/Cas Systems towards Next-Generation Biosensing

CRISPR-cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia

SHERLOCK: nucleic acid detection with CRISPR nucleases

CRISPR-Cas12-based detection of SARS-CoV-2

A protocol for detection of COVID-19 using CRISPR diagnostics

CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design

The expanded development and application of CRISPR system for sensitive nucleotide detection

CRISPR-Cas Systems for Diagnosing Infectious Diseases

Next-generation pathogen diagnosis with CRISPR/Cas-based detection methods

Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection

Serology testing in the COVID-19 pandemic response

COVID-19 Serological Tests: How Well Do They Actually Perform?

Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department

Basic Mechanism and Applications

Chemiluminescent immunoassay technology: what does it change in autoantibody detection?

Enzyme-linked immunosorbent assay for the quantitative/qualitative analysis of plant secondary metabolites

Covert COVID-19 and false-positive dengue serology in Singapore

Advances in Diagnostic Approaches for Viral Etiologies of Diarrhea: From the Lab to the Field

Serological tests for COVID-19 antibodies: Limitations must be recognized

Laboratory characteristics of patients infected with the novel SARS-CoV-2 virus

Chest CT in COVID-19 pneumonia: A review of current knowledge

Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: Interim guidance

Outbreak communication -Best practices for communicating with the public during an outbreak

Point-Of-Care Testing Curriculum and Accreditation for Public Health-Enabling Preparedness, Response, and Higher Standards of Care at Points of Need

Diagnostic preparedness for infectious disease outbreaks

Clinical translation of the assets of biomedical engineering -a retrospective analysis with looks to the future

A Precision Medicine Approach to SARS-CoV-2 Pandemic Management

Large-Scale Multiomic Analysis of COVID-19 Severity

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection

The Role of Interleukin 6 During Viral Infections

Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Comparative genomics as a tool to understand evolution and disease

Genome-Wide Association Studies

Epidemiological Evidence of an Association between SLC6A2 Gene Polymorphism and Hypertension

SLC6 transporters: Structure, function, regulation, disease association and therapeutics

VEGF-D: a novel biomarker for detection of COVID-19 progression

Emerging Roles for VEGF-D in Human Disease

D-dimer pitfalls and performance in COVID-19

Systems Biology Approaches for Therapeutics Development Against COVID-19

COVID-19 Pandemic: Hopes from Proteomics and Multiomics Research

Potential of multiomics technology in precision medicine

From Big Data to Precision Medicine

Burnham-marusich, Point-of-Care Testing for Infectious Diseases: Past, Present, and Future Thomas

Point of care testing for infectious diseases

Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence

Current status, advances, challenges and perspectives on biosensors for COVID-19 diagnosis in resource-limited settings

Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects

The rise of point-of-care genetics: how the SARS-CoV-2 pandemic will accelerate adoption of genetic testing in the acute setting

Point-of-Care Testing for Infectious Diseases: Past, Present, and Future

Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing: Updated

Ontario Agency for Health Protection and Promotion (Public Health Ontario), The use of alternate sample collection methods for COVID-19 PCR testing

Consistent Detection of 2019 Novel Coronavirus in Saliva

Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2

Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection

Development of a point-of-care test to detect SARS-CoV-2 from saliva which combines a simple RNA extraction method with colorimetric reverse transcription loop-mediated isothermal amplification detection

Exploring salivary diagnostics in COVID-19: a scoping review and research suggestions

Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis

Diagnostic biosensors in medicine -A review

Electrochemical aptasensor for the detection of HER2 in human serum to assist in the diagnosis of early stage breast cancer

Electrochemical DNA biosensor for the detection of human papillomavirus E6 gene inserted in recombinant plasmid

Toward a point-of-care diagnostic for specific detection of Mycobacterium tuberculosis from sputum samples

DNA biosensor as a confirmatory test: Studies of household cleaners effects of onto electrochemical DNA detection

History of blood gas analysis. IV. Leland Clark's oxygen electrode

Introduction to biosensors

Point-ofcare biosensors in medicine: a brief overview of our achievements in this field based on the conducted research in EMRI (endocrinology and metabolism research Institute of Tehran University of medical sciences) over the past fourteen years

Personalized medicine": What's in a name?

Biosensors for Personal Mobile Health: A System Architecture Perspective

Wireless Biological Electronic Sensors

Internet of Things in Healthcare: A Brief Overview

Review-Deep Learning Methods for Sensor Based Predictive Maintenance and Future Perspectives for Electrochemical Sensors

Biosensors Market Research Report by Type , by Product , by Technology , by Industry -Global Forecast to 2025 -Cumulative Impact of COVID-19

by-Type-by-Product-by-Technology-by-Industry-Global-Forecast-to-Cumulative-Impact-of-COVID-19.html

Electrochemical Biosensors: Recommended Definitions and Classification

An overview of biomolecules, immobilization methods and support materials of biosensors

Electrochemical DNA biosensors: a review

Electrochemical biosensors: perspective on functional nanomaterials for on-site analysis

Status of biomolecular recognition using electrochemical techniques

Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of COVID-19

Electrochemical nucleic acid-based biosensors: Concepts, terms, and methodology

Immunodiagnostics and immunosensor design

The Role of Electrochemical Immunosensors in Clinical Analysis

Electrochemical genosensor design: immobilisation of oligonucleotides onto transducer surfaces and detection methods

Electrochemical biosensors based on nucleic acid aptamers

Aptamers: molecular tools for analytical applications

Methods and Applications of In Silico Aptamer Design and Modeling

Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology

Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic J o u r n a l P r e -p r o o f Applications?

A Sensitive and Selective Label-Free Electrochemical DNA Biosensor for the Detection of Specific Dengue Virus Serotype 3 Sequences

Electrochemical DNA biosensor for human papillomavirus 16 detection in real samples

Electrochemical DNA biosensor for bovine papillomavirus detection using polymeric film on screen-printed electrode

Rapid and unamplified identification of COVID-19 with morpholino-modified graphene field-effect transistor nanosensor

Morpholino Antisense Oligomers: Design, Preparation, and Properties

Molybdenum disulfide field-effect transistor biosensor for ultrasensitive detection of DNA by employing morpholino as probe

Electroanalytical Application of Carbon Based Electrodes to the Pharmaceuticals

Electrode Materials in Modern Organic Electrochemistry

A review on recent advancements in electrochemical biosensing using carbonaceous nanomaterials

Carbon based materials for electronic bio-sensing

Electrosynthesized polymers for biosensing

Electropolymerization, InTech

Conducting Polymers with Superhydrophobic Effects as Anticorrosion Coating

Electrochemical Deposition of Nanomaterials for Electrochemical Sensing

Surface-Immobilized Biomolecules

A Comprehensive Review of the Covalent Immobilization of Biomolecules onto Electrospun Nanofibers

Recent Advances in Immobilization Strategies for Biomolecules in Sensors Using Organic Field-Effect Transistors

A one-step method for covalent bond immobilization of biomolecules on silica operated in aqueous solution

Novel approaches for biomolecule immobilization in microscale systems

Towards a review of the EC Recommendation for a definition of the term "nanomaterial" -Part 3 -Scientific-technical evaluation of options to clarify the definition and to facilitate its implementation

Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations

Nanomaterial-based biosensors for biological detections

Nanoparticles: Properties, applications and toxicities

Biosensor Applications of Electrodeposited Nanostructures

Bionanomaterial-based electrochemical biosensing platforms for biomedical applications

Nanomaterials for biosensing applications: a review

Deposition of nanomaterials: A crucial step in biosensor fabrication

Nanomaterials for molecular signal amplification in electrochemical nucleic acid biosensing: recent advances and future prospects for point-of-care diagnostics

Nanopore blockade sensors for ultrasensitive detection of proteins in complex biological samples

Fabrications, Applications and Challenges of Solid-State Nanopores: A Mini Review

A biosensing expedition of nanopore: A review

Direct electrical quantification of glucose and asparagine from bodily fluids using nanopores

Nanopore Electrochemistry: A Nexus for Molecular Control of Electron Transfer Reactions

Ultrasensitive cDNA Detection of Dengue Virus RNA Using Electrochemical Nanoporous Membrane-Based Biosensor

An ultrasensitive label free human papilloma virus DNA biosensor using gold nanotubes based on nanoporous polycarbonate in electrical alignment

Rapid SARS-CoV-2 Detection Using Electrochemical Immunosensor

eCovSens-Ultrasensitive Novel In-House Built Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19 antigen, a spike protein domain 1 of SARS-CoV-2

The origins and the future of microfluidics

Microfluidic Point-of-Care Testing: Commercial Landscape and Future Directions

A high-throughput multiplexed microfluidic device for COVID-19 serology assays

Wireless biosensors for POC medical applications

An Integrated Wearable Wireless Vital Signs Biosensor for Continuous Inpatient Monitoring

United Nations Children's Fund (UNICEF)

Mechanical fault diagnosis and prediction in IoT based on multi-source sensing data fusion

Review of Machine Learning Approaches In Fault Diagnosis applied to IoT Systems

Sensitive electrochemical DNA sensor for the detection of HIV based on a polyaniline/graphene nanocomposite

Ultrasensitive and Highly Selective Electrochemical Biosensor for HIV Gene Detection Based on Amino-Reduced Graphene Oxide and β-cyclodextrin Modified Glassy Carbon Electrode

Detection of chikungunya virus DNA using two-dimensional MoS2 nanosheets based disposable biosensor

Detecting the DNA of dengue serotype 2 using aluminium nanoparticle doped zinc oxide nanostructure: Synthesis, analysis and characterization

Electrical pulseinduced electrochemical biosensor for hepatitis E virus detection

Portable Laboratory Platform With Electrochemical Biosensors for Immunodiagnostic of Hepatitis C Virus

Impedimetric anti-dengue antibodies using functional carbon nanotube deposits validated with blood plasma assays

An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes

Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor

Nucleic aptamer modified porous reduced graphene oxide/MoS2 based electrodes for viral detection: Application to human papillomavirus (HPV)

Ultra-sensitive aptasensor based on a GQD nanocomposite for detection of hepatitis C virus core antigen

Design of aptamer-based sensing platform using gold nanoparticles functionalized reduced graphene oxide for ultrasensitive detection of Hepatitis B virus

Subtyping of influenza A H1N1 virus using a label-free electrochemical biosensor based on the DNA aptamer targeting the stem region of HA protein

[259]* HEV-like particles; ** influenza A mini-hemagglutinin protein a Pencil graphite electrode; b Glassy carbon electrode; C Silver-interdigitated electrode; d nanoporous polycarbonate; e graphene-based field-effect transistor; f Carbon electrode; g Screen-printed carbon electrode; h Graphene carbon; i Indium tin oxide-coated glass 1 Polyaniline + Graphene; 2 Amino-reduced graphene oxide (NH2-rGO)+ β-cyclodextrin (β-CD); 3 molybdenum disulphide nanosheets (MoS2 NSs); 4 ZnO nanostructures doped with Aluminium nanoparticle + Silicon wafers; 5 Gold nanoparticle (AuNP); 6 Gold nanotubes (AuNTs); 7 Specific anti-HEV antibody -conjugated to nitrogenand sulfur-codoped graphene quantum dots (Ab-N, S-GQDs) + gold; embedded polyaniline nanowires (AuNP-PAni); 8 N-hydroxysuccinimide 11-(pyrrol-1-yl) undecanoate (Poly-pyrrole-NHS) + multi-walled carbon nanotubes (CNT); 9 Porous reduced graphene oxide + molybdenum sulfide; 10 Graphene Quantum Dots.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Highlights  SARS-CoV-2 is responsible for causing the COVID-19 (coronavirus disease-

 Multiple SARS-CoV-2 variants circulating in the world  There are still many challenges to overcome the COVID-19 pandemic  Fast diagnostic is the "key tool" for effective containment of a pandemic; Biosensors can be the ideal diagnostic tools for pandemic scenarios.J o u r n a l P r e -p r o o f